Raymond James stock outperforms as JMP reiterates $180 price target

Raymond James (RJF) reported fiscal third-quarter adjusted earnings per share of $2.18, which included a $0.29 negative impact from a one-time $58 million legal settlement. Excluding this charge, EPS would have been $2.47, surpassing analyst estimates of $2.42 and consensus of $2.36, while net revenues of $3.4 billion also exceeded models by approximately $25 million. Citizens JMP reiterated a Market Outperform rating and $180 price target, with InvestingPro analysis suggesting the financial services firm remains undervalued despite higher core non-compensation expenses and a slightly elevated compensation ratio.

Analysis

Raymond James (RJF) reported mixed fiscal third-quarter results, where the headline figures mask underlying operational strength. The company's reported adjusted EPS of $2.18 was impacted by a one-time, non-operational legal settlement of $58 million, which reduced EPS by $0.29. Excluding this charge, the core EPS would have been $2.47, comfortably exceeding both the analyst estimate of $2.42 and the consensus forecast of $2.36. This underlying earnings beat was supported by solid top-line performance, with net revenues of $3.4 billion surpassing models by approximately $25 million and demonstrating robust 13.4% growth over the last twelve months. However, profitability was slightly pressured by core non-compensation expenses that were $23 million higher than modeled and a compensation ratio of 64.5%, slightly above the 64% expectation. A lower-than-expected tax rate of 22.7% provided a partial offset, contributing about $0.05 to EPS. The company's reiteration of its full-year non-compensation expense guidance suggests these cost pressures are viewed as manageable.

Key Decisions for Investors

• Investors should look past the headline EPS miss and focus on the firm's core earnings power, as the underlying EPS of $2.47 beat estimates, signaling solid operational health.
• While revenue growth is strong, it is crucial to monitor non-compensation expenses and the compensation ratio in subsequent quarters to ensure margin discipline is maintained.
• Given the reiterated Market Outperform rating, a 13.7x P/E ratio, and the non-recurring nature of the legal charge, any negative market reaction to the reported EPS could present a buying opportunity for investors focused on fundamental value.